Results 161 to 170 of about 16,074 (213)

Effect of 1-deamino-8-D-arginine vasopressin on the prolonged bleeding time in chronic renal failure.

Nephron, 1982
The prolonged bleeding times of 12 patients with chronic renal failure were significantly shortened at 1 and 2 h after an infusion of 0.4 microgram/kg 1-deamino-8-D-arginine vasopressin (DDAVP).
A. Watson, J. Keogh
semanticscholar   +1 more source

Response to 1-deamino-8-D-arginine vasopressin in von Willebrand disease.

Haemostasis, 1994
The synthetic agent, 1-deamino-8-D-arginine vasopressin (DDAVP), is generally regarded to be the treatment of choice for persons with type I von Willebrand disease (vWD), and may be useful in type IIA vWD as well.
J. Lusher
semanticscholar   +1 more source

Normal response of factor VIII and von Willebrand factor to 1-deamino-8D-arginine vasopressin in nephrogenic diabetes insipidus.

Journal of Clinical Endocrinology and Metabolism, 1988
The effects of 1-deamino-8D-arginine vasopressin (DDAVP) on plasma factor VIII and von Willebrand factor (vWF) levels were studied in four patients with nephrogenic diabetes insipidus (NDI) from two unrelated families. While the urine osmolality remained
B. Brenner, U. Seligsohn, Z. Hochberg
semanticscholar   +1 more source

Absorption of 1-deamino-8-D-arginine vasopressin from different regions of the gastrointestinal tract in rabbits.

Acta Endocrinologica, 1986
By using a specific radioimmunoassay for 1-deamino-8-D-arginine vasopressin (DDAVP), plasma concentrations were measured in rabbit plasma at various times after intra-gastrointestinal injections.
S. Lundin, H. Vilhardt
semanticscholar   +1 more source

Central diabetes insipidus in children. Antidiuretic effect and pharmacokinetics of intranasal and peroral 1-deamino-8-D-arginine vasopressin.

Acta Endocrinologica, 1987
The antidiuretic effect and pharmacokinetics of 10 to 20 micrograms of intranasal (IN) and 200 to 400 micrograms of oral (po) 1-deamino-8-D-arginine vasopressin (DDAVP) were studied in 10 paediatric diabetes insipidus patients.
A. Fjellestad-Paulsen, N. Tubiana-Rufi, A. Harris, P. Czernichow   +3 more
semanticscholar   +1 more source

Design of potent and selective agonists for the human vasopressin V1b receptor based on modifications of [deamino-cys1]arginine vasopressin at position 4.

Journal of Medicinal Chemistry, 2004
The glutamine(4) residue in [deamino-Cys(1)]arginine vasopressin (dAVP) was replaced by a broad series of aliphatic, aromatic, polar, and charged amino acids to give the following peptides: d[Gly(4)]AVP (1), d[Ala(4)]AVP (2), d[Abu(4)]AVP (3), d[Nva(4 ...
L. Cheng, S. Stoev, M. Manning, S. Derick, A. Peña, Mohamed Slim Ben Mimoun, G. Guillon   +6 more
semanticscholar   +1 more source

Subcutaneous and intranasal administration of 1-deamino-8-d-arginine vasopressin in the assessment of renal concentration capacity.

Nephron, 1987
Maximum urine concentration capacity was studied in healthy adults using different routes and doses of administration of 1-deamino-8-d-arginine vasopressin (DDAVP)-desmopressin.
N. Tryding, G. Sterner, B. Berg, A. Harris, S. Lundin   +4 more
semanticscholar   +1 more source

Design and synthesis of the first selective agonists for the rat vasopressin V(1b) receptor: based on modifications of deamino-[Cys1]arginine vasopressin at positions 4 and 8.

Journal of Medicinal Chemistry, 2007
The neurohypophyseal peptides arginine vasopressin (AVP) and oxytocin (OT) mediate a wide variety of peripheral and central physiological and behavioral effects by acting on four different G-protein coupled receptors, termed V1a (vascular), V1b ...
A. Peña, B. Murat, M. Trueba, M. Ventura, N. Wo, H. Szeto, L. Cheng, S. Stoev, G. Guillon, M. Manning   +9 more
semanticscholar   +1 more source

1-Deamino-8-D-arginine vasopressin in the treatment of non-haemophilic patients with acquired factor VIII inhibitor.

Haemostasis, 1990
1-Deamino-8-D-arginine vasopressin (DDAVP) was administered to 3 patients with spontaneous factor VIII inhibitors. In 2 patients with baseline factor VIII levels above 1%, a marked increase of factor VIII activity after DDAVP infusion could be observed ...
M. Muhm, N. Grois, P. Kier, A. Stümpflen, P. Kyrle, I. Pabinger, P. Bettelheim, W. Hinterberger, K. Lechner   +8 more
semanticscholar   +1 more source

Normal hemodynamic and coagulation responses to 1-deamino-8-D-arginine vasopressin in a case of lithium-induced nephrogenic diabetes insipidus. Results of treatment by a prostaglandin synthesis inhibitor (indomethacin).

Hormone Research, 1992
The effect of 1-deamino-8-D-arginine vasopressin (DDAVP) on mean arterial pressure, pulse rate (PR), plasma renin activity (PRA), plasma factor VIIIc and von Willebrand factor were studied in a case of persistent lithium-induced nephrogenic diabetes ...
C. Hober, M. Vantyghem, A. Racadot, J. Cappoen, J. Lefebvre   +4 more
semanticscholar   +1 more source